

Ramucirumab shows promise in care of advanced gastric cancer

October 24 2017



(HealthDay)—Ramucirumab appears to be safe and effective for the

treatment of advanced gastric cancer, according to a study published online Sept. 29 in the *Journal of Gastroenterology and Hepatology*.

Kei Muro, M.D., from Aichi Cancer Center Hospital in Japan, and colleagues conducted subgroup analyses the REGARD and RAINBOW trials. Both were global, phase 3, randomized, double-blind trials of second-line [ramucirumab](#) for metastatic gastric or gastroesophageal junction adenocarcinoma.

The researchers found that the hazard ratios (HRs) for overall survival favored treatment with ramucirumab in the REGARD study: ≤ 45 years (HR, 0.59; 95 percent confidence interval [CI], 0.27 to 1.26);

Citation: Ramucirumab shows promise in care of advanced gastric cancer (2017, October 24) retrieved 11 May 2024 from <https://medicalxpress.com/news/2017-10-ramucirumab-advanced-gastric-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.